Retatrutide (LY3437943, also referred to informally as "reta peptide") is a synthetic 39-amino-acid peptide developed by Eli Lilly that acts simultaneously on three distinct metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor
To investigate, the team focused on an enzyme called PAM (short for peptidyl-glycine alpha-amidating monooxygenase), and the gene that encodes it
Conversely, in another study with 10 healthy adults where glucose levels were maintained between 70 80 mg/dL, fat ingestion elicited a fivefold to sixfold rise in GIP levels without concomitant insulin secretion (119)
A lower starting dose may also help patients maintain consistency while progressing gradually
Well also emphasize the importance of hygiene, such as cleaning the skin with an alcohol swab before each injection